A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile
Recently, a series of highly effective peptide- or protein-based HIV fusion inhibitors have been identified. However, due to their short half-life, their clinical application is limited. Therefore, the development of long-acting HIV fusion inhibitors is urgently needed. Here, we designed and constru...
Saved in:
Main Authors: | Wei Xu (Author), Zhe Cong (Author), Qianyu Duan (Author), Qian Wang (Author), Shan Su (Author), Rui Wang (Author), Lu Lu (Author), Jing Xue (Author), Shibo Jiang (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Engineering of a Long-Acting Bone Morphogenetic Protein-7 by Fusion with Albumin for the Treatment of Renal Injury
by: Mei Takano, et al.
Published: (2022) -
A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
by: Jie Zhou, et al.
Published: (2022) -
Long-term economic evaluation of the recombinant Mycobacterium tuberculosis fusion protein (EC) test for the diagnosis of Mycobacterium tuberculosis infection
by: Sha Diao, et al.
Published: (2023) -
Superior Treg-Expanding Properties of a Novel Dual-Acting Cytokine Fusion Protein
by: Tanja Padutsch, et al.
Published: (2019) -
Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
by: Francisco José Toja-Camba, et al.
Published: (2021)